Stryker (NYSE:SYK) Director Ronda Stryker Sells 250,000 Shares

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Stryker Trading Down 1.1%

SYK opened at $358.49 on Friday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $358.39 and a 200-day simple moving average of $370.85. The firm has a market cap of $137.09 billion, a P/E ratio of 42.68, a P/E/G ratio of 2.12 and a beta of 0.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the previous year, the business earned $4.01 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the last quarter. State Street Corp boosted its holdings in shares of Stryker by 1.0% in the 2nd quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after buying an additional 150,204 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Stryker by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after buying an additional 79,654 shares during the last quarter. Alliancebernstein L.P. raised its stake in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Finally, Norges Bank purchased a new stake in Stryker in the second quarter valued at $1,882,173,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Truist Financial reduced their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Barclays reiterated an “overweight” rating and issued a $469.00 target price on shares of Stryker in a report on Monday. Evercore set a $390.00 price target on Stryker in a report on Monday, January 5th. Finally, BTIG Research lifted their price objective on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Twelve equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $426.94.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.